Seasonal influenza, respiratory syncytial virus (RSV), and COVID-19 are actively circulating throughout the United States.

The first paediatric patient for Dimerix’s ACTION3 phase III clinical trial into a rare kidney disease has been recruited at ...

The following is a summary of “Monocytic reactive oxygen species-induced T cell apoptosis impairs cellular immune response to ...

Peptides have emerged as a focal point in molecular and biological research, providing a promising avenue for understanding ...

placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Planned blinded interim data ...

This ACTION3 phase III trial is a randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II ...

Abstract We investigated the effects of angiotensin II (Ang II) type 1 receptor blockade with losartan on the renin-angiotensin-aldosterone system in hypertensive patients (supine diastolic blood ...

The probability of event-free survival in patients receiving valsartan 160 mg b.i.d. vs. placebo in addition to optimal medical therapy in patients with systolic heart failure (Kaplan-Meier ...

This phase III trial is a randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor ...

Earlier this week, Warner Bros. officially pushed The Batman Part II from its October 2026 release date and delayed the sequel for another year. Now, DC Studios co-CEO James Gunn has weighed in on ...